Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.

Phase 2 Terminated 105 enrolled Centre Oscar Lambret National Cancer Institute, France · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Interest of continuing systemic chemotherapy or not , after a short initial treatment (6 weeks) in patients who are in response or stable disease("Discontinuation design ")of patients with metastatic oesophageal cancer of squamous cell type The secondary aims would be to study : toxicity, the overall survival rate, a study of costs and quality of life.

Timeline

Start: 2011-01
Primary completion: 2016-01
Completion: 2017-01

Publications

Kotecki N, Hiret S, Etienne PL, Penel N, Tresch E, Francois E, Galais MP, Ben Abdelghani M, Michel P, Dahan L, Ghiringelli F, Bedenne L, Samalin E, Piessen G, Bennouna J, Peugniez C, El Hajbi F, Clisant S, Kramar A, Mariette C, Adenis A. First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control. Oncology. 2016;90(2):88-96. doi: 10.1159/000442947. Epub 2016 Jan 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	50 mg/m2	—
Subject	Cisplatin	Other / unclassified	60 mg/m2	—
Subject	Cisplatin	Other / unclassified	70 mg/m2	—
Subject	Cisplatin	Other / unclassified	75 mg/m2	—
Subject	Docetaxel	Small molecule	30 mg/m2	—
Subject	Docetaxel	Small molecule	50 mg/m2	—
Subject	Oxaliplatin	Small molecule	85 mg/m2	—
Subject	elvorin	Unknown	200 mg/m2	Intravenous
Subject	elvorin	Unknown	500 mg/m2	Intravenous
Subject	fluorouracil	Small molecule	200 mg/m2	—
Subject	fluorouracil	Small molecule	400 mg/m2	—
Subject	fluorouracil	Small molecule	600 mg/m2	—
Subject	fluorouracil	Small molecule	700 mg/m2	—
Subject	fluorouracil	Small molecule	800 mg/m2	—

Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.

Summary

Timeline

Publications

Drugs

Indications